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Summary
A common polymorphism at codon 192 in the human
paraoxonase (PON) 1 gene has been shown to be as-
sociated with increased risk for coronary heart disease
(CHD) in Caucasian populations. However, these find-
ings have not been reported consistently in all Caucasian
and non-Caucasian populations, suggesting that this is
not a functional mutation but may mark a functional
mutation present in either PON1 or a nearby gene. Re-
cently, two other PON-like genes, designated “PON2”
and “PON3,” have been identified, and they are linked
with the known PON1 gene on chromosome 7. Iden-
tification of additional polymorphisms in the PON-gene
cluster may help to locate the functional polymorphism.
In this report, we describe the existence of a common
polymorphism at codon 311 (CysrSer; PON2*S) in the
PON2 gene, as well as its association with CHD alone
and in combination with the PON1 codon 192 poly-
morphism in Asian Indians. The frequency of the
PON2*S allele was significantly higher in cases than in
controls (.71 vs. .61; ). The age- and sex-ad-P  .016
justed odds ratio (OR) was 2.5 (95% confidence interval
; ) for the PON2*S allele[95% CI]  1.8–3.1 P  .0090
carriers. Further stratification of the PON2*S associa-
tion, on the basis of the presence or absence of the
PON1*B allele, showed that the CHD risk associated
with the PON2*S allele was confined to PON1*B-allele
carriers. Likewise, the PON1*B-allele risk was present
only among PON2*S carriers. Age- and sex-adjusted
ORs for the PON2*S and PON1*B were 3.6
( ; ) and 2.9 (95% CI  2.6–4.6 P  .011 95% CI 
; ) among the PON1*B and PON2*S2.4–3.5 P  .0002
carriers, respectively. Our data indicate that both poly-
morphisms synergistically contribute to the CHD risk in
this sample and that this genetic risk is independent of
the conventional plasma lipid profile.
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Introduction
Oxidized LDL is believed to play an important role in
initiation of atherosclerosis. Numerous studies suggest
the formation of fatty-acid streaks in response to a series
of events, followed by the migration of oxidized LDL-
loaded monocytes into the subendothelial space of the
arteries (Navab et al. 1996). HDL has been shown to
prevent oxidative modification of LDL in vivo (Klimov
et al. 1993) as well as in vitro (Mackness et al. 1993).
Recent studies indicate that two HDL-associated en-
zymes, PON and platelet-activating–factor acetyl hydro-
lase, are responsible for its antioxidative and anti-in-
flammatory properties (Stafforini et al. 1993; Watson et
al. 1995). In vitro studies indicate that PON can signif-
icantly reduce lipid peroxide generation during LDL ox-
idation and thus may provide HDL-associated protec-
tion against atherosclerosis. Furthermore, serum PON
activity has been found to be lower in patients with
myocardial infarction (MI) (McElveen et al. 1986), di-
abetes and familial hypercholesterolemia (Mackness et
al. 1991), fish-eye disease (Mackness et al. 1987), and
Tangier disease (Mackness et al. 1989). PON tightly
binds to HDL subfractions that also contain apolipo-
protein (apo) A-I and apo J (Blatter Garin et al. 1993;
Kelso et al. 1994). PON has largely been studied for its
role in hydrolyzing a large number of organophosphate
compounds used in pesticides, insecticides, and nerve
gases (La Du 1992; Davies et al. 1996). Serum PON
levels and activity vary widely among populations of
different ethnic backgrounds (Diepgen et al. 1986; Roy
et al. 1991). Human serum PON (now called “PON1”)
is genetically polymorphic, because of the occurrence of
two common isoforms that differ by substitution of an
amino acid (GlnrArg) at codon 192 (Adkins et al. 1993;
Humbert et al. 1993). Individuals homozygous for Gln
(the A allele) have lower PON activity than is seen in
individuals homozygous for Arg (the B allele), the latter
having eight times more activity than has Gln in hydro-
lyzing paraoxon (Davies et al. 1996; La Du 1996). PON
activity is substrate dependent andmay be quite opposite
for different substrates (Furlong et al. 1988; La Du et
al. 1988; Davies et al. 1996). Notably, compared with
the PON1 A variant, the PON1 B variant is more effi-
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Table 1
Demographic, Clinical, and Lipid Profile of Asian Indian Controls
and Cases
VALUES INa
PControls Cases
Males/Females 144/45 115/14 )
Age (Years) 49.6  .8 55.20  .8 .001
BMI (kg/m2) 24.9  .3 24.85  .3 .79
Smokers (0/1/2)b 166/0/23 71/26/29c )
Nondiabetic/
diabetic
169/20 89/40 )
Non-MI/MI 189/0 46/69d )
HDL cholesterol
(mg/dl)
41.3  1.0 27.3  .8 .0001
LDL cholesterol
(mg/dl)
165.5  4.3 155.5  3.9 .11
Total cholesterol
(mg/dl)
241.4  5.3 216.3  4.1 .001
Triglycerides (mg/
dl)e
149.0  6.0 150.7  6.3 .84
Apo A-I (mg/dl) 141.9  2.0 98.3  5.0 .0001
Apo B (mg/dl) 136.0  2.7 105.4  2.6 .000
a NOTE.—Mean  SE values are for continuous variables.
b The three numerals indicate, respectively, the number of individuals
who have never been smokers, who once were smokers, and who
currently are smokers.
c Smoking history was not known for 3 individuals.
d MI information was not available for 15 individuals.
e Values are log transformed.
Figure 1 Restriction patterns of the PCR-amplified 262-bp frag-
ment after digestion with DdeI. Fragment sizes of 142 bp and 120 bp
correspond to Cys311 (C allele), whereas 75 bp and 67 bp are diag-
nostic bands for Ser311 (S allele). Note that a 120-bp band is present
in all genotypes, because of the presence of a commonDdeI site. Lanes
1, 4, and 5, SS genotype. Lanes 2 and 6, CC genotype. Lane 3, CS
genotype.
cient in hydrolyzing paraoxon but is less efficient in hy-
drolyzing three additional organophosphates: diazoxon,
sarin, and soman (Davies et al. 1996). Recently, the B
allele of the PON1 codon 192 polymorphism has been
found to be associated with an increased risk of CHD
(Ruiz et al. 1995; Serrato and Marian 1995). Our own
study, conducted in Asian Indians and Chinese, has in-
dicated that the B allele is a significant risk factor for
CHD in Asian Indians but not in Chinese (Sanghera et
al. 1997). Two additional studies, in Caucasians, re-
ported a lack of association of the B allele with CHD
(Antikainen et al. 1996; Herrman et al. 1996), suggesting
that the B allele may act merely as a marker for an as
yet unidentified functional mutation in either PON1 or
a nearby gene.
In addition to the known human PON1 gene, two
additional PON-like genes, designated “PON2” and
“PON3,” have been identified, and all three genes have
been mapped to chromosome 7q21-q22 (Primo-Parmo
et al. 1996a, 1996b). In the present study, we describe
the existence of a common polymorphism at codon 311
in the PON 2 gene, as well as its association with CHD
risk both alone and in combination with the PON1 co-
don 192 polymorphism in Asian Indians.
Subjects and Methods
All subjects included in this study are Asian Indians
and are second- or third-generation descendants of im-
migrants who migrated from the Indian subcontinent to
Singapore during the early 19th century. There is a very
low degree of interracial marriage in Singapore. On the
basis of self-reports, no subjects with mixed ancestry
were encountered.
CHD Cases
The study samples comprised 129 unrelated CHD
cases (115 males and 14 females) with an age range of
32–83 years ( [ ]mean standard error mean SE
years). The cases were consecutive CHD pa-55.2 0.8
tients admitted to the Cardiothoracic Surgery Unit at the
Singapore General Hospital, for coronary-artery-bypass
graft, between August 1989 and December 1992. Blood
samples from cases were collected either during preop-
erative review or, for those with a history of MI, x3
mo after full recovery. Cases with a positive stress test
(Bruce method) were evaluated for the presence of CHD
by means of coronary angiography. Inclusion criteria
were 150% narrowing of the lumina of at least one of
the major coronary arteries. A detailed family history of
CHD, hypertension, diabetes mellitus, angina, and
smoking history was obtained from each case by a cer-
tified physician and cardiologist. MI had occurred in
∼60% of the cases, as judged both by typical electro-
cardiogram (ECG) changes (Minnesota code 1.1 or 1.2
in the ECG) and by changes in serum enzymes (aspartate
aminotransferase, lactate dehydrogenase, and creatine
kinase); and nearly 31% of the cases were diabetic. Cases
with less obstruction or with valvular disease were
excluded.
Controls
Unrelated controls ( ) of age 132 yearsn  189
( years) were selected from amean SE 49.6 0.8
larger, population-based control sample of 470 Asian
Indians, to match the age range of cases. The control
samples were collected as part of the Healthy Lifestyle
Promotion Exercise study. All participants completed
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Table 2
Distribution of PON1 and PON2 Genotype and Allele Frequencies
in Cases and Controls
Controls
(n  190)
Cases
(n  157)
PON1:
Genotype:
AAa 91 (47.9%) 42 (26.8%)
ABb 76 (40.0%) 85 (54.1%)
BBc 23 (12.1%) 30 (19.1%)
Allele:
A (Gln) .679 .538
B (Arg)d .321 .462
(n  189) (n  129)
PON2:
Genotype:
CC 33 (17.5%) 14 (10.9%)
CS 80 (42.3%) 48 (37.2%)
SSe 76 (40.2%) 67 (51.9%)
Allele:
C (Cys) .386 .295
S (Ser)f .614 .705
a Significant difference between cases and controls: P ! .0001.
b Significant difference between cases and controls: P ! .01.
c Significant difference between cases and controls: P ! .025.
d Significant difference between cases and controls: P  .0001.
e Significant difference between cases and controls: P ! .05.
f Significant difference between cases and controls: P  .016.
Table 3
Assessment of Hardy-Weinberg Equilibrium for PON
Polymorphisms
HETEROZYGOSITY (95% CI)
x2 a P aObserved Expected
PON1:
Controls .40 (.35–.45) .44 1.28 .26
Cases .54 (.49–.60) .50 1.25 .26
PON2:
Controls .42 (.37–.47) .47 2.18 .14
Cases .37 (.31–.43) .42 1.44 .23
a Calculated by use of all three genotypes, for each PON genotype
and subject sample.
questionnaires including a complete medical and family
history of hypertension, CHD, any other significant ill-
ness, and (in women) hormone therapy. Only those sub-
jects who were healthy and had no family history of
CHD were included in the control group. Individuals
were selected after careful physical examination, chest
x-ray, ECG, and urine and blood tests including those
for hemoglobin and glucose.
Clinical and Metabolic Estimations
Recumbent blood pressure and 12-lead ECG were re-
corded on each subject after a 30-min rest on a couch.
Body weight, height, and waist and hip measurements
were recorded, and blood samples were collected by ve-
nipuncture after an overnight fast. Details of methods
of quantitative estimations of apolipoproteins and lipo-
protein lipids have been provided elsewhere (Sanghera
et al. 1997).
PON-Polymorphism Screening
DNA was extracted from buffy coats as described by
Parzer and Mannhalter (1991) and was used to amplify
the target region in the PON1 and PON2 genes by PCR.
Details of primers and PCR conditions for the PON1
codon 192 polymorphism have been described elsewhere
(Sanghera et al. 1997).
On the basis of a comparison between the DNA se-
quence submitted to the dbEST database and those ob-
tained by Primo-Parmo et al. (1996b) in their cDNA and
genomic DNA for PON2, the occurrence of a possible
polymorphism, having either TCT (Ser) or TGT (Cys),
was predicted at codon 311. Using DNA data submitted
to GSDB, we designed primers flanking the region con-
taining codon 311, to amplify a 262-bp fragment, which
was followed by restriction digestion withDdeI, and we
found the existence of a common polymorphism in
Asian Indians. The forward primer PON2 F9 (5′-ACA
TGC ATG TACGGT GGT CTT ATA-3′) and the reverse
primer PON2 R9 (5′-AGC AAT TCA TAG ATT AAT
TGT TA-3′) were used to amplify the target region. One
microgram of genomic DNA was amplified in 50 ml of
reaction mixture containing 0.3 mM of each primer, 200
mM of each dNTP (Pharmacia), 5 ml of 10 # reaction
buffer (100 mM Tris-HCL [pH 9.0], 500 mM KCL, and
1% Triton X-100), 5% dimethyl sulfoxide, 1.5 mM
MgCl2, and 1.25 units Taq DNA polymerase. After the
DNA was denatured for 4 min at 94C, the reaction
mixture was subjected to 30 cycles of denaturation for
1 min at 94C, annealing for 1.5 min at 50C, and ex-
tension for 2 min at 72C. The PON1 and PON2 poly-
morphisms were detected by digesting the PCR-ampli-
fied product with theAlwI andDdeI restriction enzymes,
respectively, followed by size fractionation in 3% Nu-
sieve (FMC) agarose gels and visualization of bands with
ethidium bromide.
Statistical Analyses
Allele frequencies were calculated by allele counting.
Concordance of genotype frequencies with Hardy-Wein-
berg equilibrium was tested by a x2 goodness-of-fit test.
Observed heterozygosity was estimated on the basis of
the observed proportion of heterozygotes in the sample,
ht, with the 95% CI given by ,1.96# ht (1 ht) /n
where n is the total number of individuals in the sample;
the expected heterozygosity was calculated as ˆht 
, where p is the allele frequency. Comparison2p (1 p)
of the genotype frequencies in cases versus those in con-
trols was calculated by a x2 test for a contingency2# k
table.
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Table 4
OR for Risk of Development of CHD, Estimated by Logistic Regression
OR (95% CI); P VALUEa
PON1 Only PON2 Only PON1 and PON2 Interaction
Ageb 3.2 (2.7–3.6); !.0001 3.4 (2.9–3.9); !.0001 3.2 (2.7–3.7); !.0001 3.2 (2.7–3.7); !.0001
Sexc .4 (0–1.0); .0095 .4 (0–1.0); .0048 .4 (0–1.1); .0054 .4 (0–1.1); .0054
PON1d 2.6 (2.1–3.0); .0001 ) 2.4 (1.9–2.9); .0007 .9 (0–2.2); .850
PON2e ) 2.5 (1.8–3.1); .0090 2.1 (1.4–2.8); .040 1.1 (.1–2.1); .870
PON1 # PON2 ) ) ) 3.3 (1.9–4.7); .090
x2 358.3 311.8 302.9 300.9
a Data are for Wald’s test; note that the 95% CI and Wald’s test assume that the OR has an approximate Gaussian distribution. An
ellipsis ()) denotes the term was not a part of the model.
b Entered as a dichotomy: !50 years versus x50 years, with !50 years as the referent group
c Entered as a dichotomy, with males as the referent group.
d Considered as a dominant effect and entered as a dichotomy, AA versus (AB, BB), with AA as the referent group.
e Considered as a dominant effect and entered as a dichotomy, CC versus (CS, SS), with CC as the referent group.
Approximate normality of the sampling distribution
of each dependent variable was tested by Lilliefor’s test
for normality (a modified Kolmogorov-Smirnov test).
The distributions of triglycerides in controls, as well as
the distributions of apo A-I, triglyceride, and total cho-
lesterol in cases, were not normal and, therefore, were
log transformed. Significant covariates for each depend-
ent trait were identified by Spearman’s correlations and
stepwise multiple linear regression with an overall 5%
level of significance. The covariates considered were the
linear effects of age, body-mass index (BMI), waist/hip
ratio, smoking history, and triglyceride levels, as covar-
iates known to affect lipoprotein-lipid levels. Age and
BMI were found to be the significant covariates in all
quantitative traits. Each dependent quantitative variable
was then adjusted to remove the effects of significant
covariates, and these adjusted variables were used in
one-way analysis of variance (ANOVA) to determine the
impact of the PON2 polymorphism on plasma lipid lev-
els. In genotype-lipid analysis, individuals with triglyc-
erides 1300 mg/dl were excluded.
The contribution of each polymorphism to CHD risk
was estimated on the basis of logistic regression for
unmatched data, to obtain ORs for both PON polymor-
phisms and for their interactions (e.g., age#
), adjusted for the effects of age and sex.PON genotype
Included ORs were tested for significance byWald’s test,
whereas overall significance for the difference between
the logistic regression models was tested by the deviance
as an approximate x2 statistic. All calculations used SPSS
for Windows statistical analysis software.
Results
Clinical and Demographic Information
Age, BMI, smoking history, and medical history, along
with the distributions of the mean quantitative lipid and
apolipoprotein levels, for controls and for cases, are
summarized in table 1.The cases were older and more
frequently were either current smokers or ex-smokers
than were the controls. Plasma LDL-cholesterol and tri-
glyceride levels did not differ appreciably between cases
and controls, whereas plasma HDL-cholesterol and apo
A-I levels were significantly lower in cases than in con-
trols ( ). Plasma apo B ( ) and totalP  .0001 P  .0001
cholesterol ( ) were significantly lower in casesP  .001
than in controls, which could be the result of controlled
diet and medication in the cases after they had under-
gone coronary-bypass surgery.
PON2 Codon 311 Polymorphism and Its Distribution
in Cases and Controls
The restriction patterns indicating the presence of
three genotypes due to the existence of two common
alleles, S (Ser311) and C (Cys311), are shown in figure
1. The distributions of the PON2 codon 311 polymor-
phism in controls and cases are given in table 2. This
table also includes the PON1 codon 192 polymorphism
for the expanded sample size for Asian Indian cases,
versus that which we had previously reported (Sanghera
et al. 1997) ( vs. ). The distribution ofn  157 n  122
the PON2 polymorphism was in Hardy-Weinberg equi-
librium, among both cases and controls (table 3). The
cases had a significantly higher frequency of the PON2/
SS genotype (52% vs. 40%; ) than was seen inP ! .05
the controls. Consequently, the frequency of the
PON2*S allele was significantly higher (.70 vs. .61;
) and the frequency of the PON2*C allele wasP  .016
significantly lower (.29 vs. .39; ) in cases thanP  .016
in controls. Compared with the PON2/CC genotype,
age- and sex-adjusted ORs for the development of CHD
in the PON2*S carriers (CS and SS genotypes) was 2.5
( ; ) (table 4, “PON2Only”95% CI  1.8–3.1 P  .0090
model). A more general, codominant model of risk for
the PON2*S allele—that is, with separate ORs for CS
and SS genotypes—did not give a significantly better fit
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Figure 2 Distribution of the PON1*B allele among PON2 gen-
otypes (CC, CS, and SS) and of the PON2*S allele among PON1
genotypes (AA, AB, and BB), in controls and cases. Note that both
the frequency of the PON1*B alleles in non–PON2*S allele carriers
(CC genotype) and the frequency of the PON2*S alleles in non-
PON1*B carriers (AA genotype) are comparable between cases and
controls; however, the frequency of the PON1*B allele increases
among PON2*S carriers, and the frequency of the PON2*S allele
increases among PON1*B carriers, in a dose-related manner, in cases
compared with controls.
to the data ( ) than was seen with this dominantP 1 .10
model. The B allele of the PON1 polymorphism was
also overrepresented in cases compared with controls
(.46 vs. .32; ). Cases had a significantly higherP  .0001
frequency of the PON1/BB (19% vs. 12%; ) andP ! .01
PON1/AB (54% vs. 40%; ) genotypes and sig-P ! .01
nificantly lower frequency of the PON1/AA genotype
(27% vs. 48%; ) than was seen in controls.P ! .0001
The age- and sex-adjusted ORs for the development of
CHD in the PON1*B carriers (AB and BB genotypes)
was 2.6 ( ; ) (table 4,95% CI  2.1–3.0 P  .0001
“PON1 Only” model ). Again, a codominant model for
risk of the PON1*B allele did not give a significantly
better fit to the data ( ) than was seen with theP 1 .10
dominant model. The association of both polymor-
phisms with the risk of CHD was independent of the
diabetic status, because the removal of the 40 diabetic
CHD cases and of the 20 diabetic controls (table 1) did
not affect these associations (data not shown).
Relationship between PON1 and PON2
Polymorphisms and CHD Risk
To investigate whether the CHD risks attributable to
PON1 (B allele) and PON2 (S allele) are additive or
interactive between the two loci, we determined the dis-
tribution of the PON2 genotypes with regard to the
PON1 polymorphism, stratified by the presence (AB and
BB genotype) or absence (AA genotype) of the PON1*B
allele, and the distribution of the PON1 genotypes with
regard to the PON2 polymorphism, stratified by the
presence (CS and SS genotype) or absence (CC genotype)
of the PON2*S allele (table 5). Although the distribution
of the PON2 genotype among non-PON1*B carriers
was similar among cases and controls, it was signifi-
cantly different among PON1*B carriers. Among
PON1*B carriers, the frequency of the PON2/CC ge-
notype was significantly lower (4% vs. 13%; )P ! .03
and the frequency of the PON2/SS genotype was sig-
nificantly higher (60% vs. 42%; ) in cases thanP ! .01
in controls. Although the frequency of the PON2*S al-
lele was comparable in cases and controls having the
PON1/AA genotype (.51 vs. .60; ), it was sig-P  .20
nificantly higher in cases than in controls, among
PON1*B carriers (.78 vs. .64; ). Also, the dis-P ! .003
tribution of the PON1*B allele was similar between
cases and controls having the PON2/CC genotype (.18
vs. .26; ) but was significantly higher amongP  .39
PON2*S carriers (.47 vs. .33; ).P ! .001
An interesting feature about the distribution of the
PON1*B-allele frequency among the PON2 genotypes
in CHD cases was that it increased gradually, from .18
in the PON2/CC genotype to .39 in the PON2/CS ge-
notype and to .51 in the PON2/SS genotype (fig. 2). This
difference was significant between the PON2/CC and CS
genotypes ( ) and between the PON2/CC andP  .015
SS genotypes ( ) (see fig. 2). This increase is alsoP ! .0001
seen in the age- and sex-adjusted ORs for the PON1
dominant model: ( ;OR  0.9 95% CI  0–2.2 P 
) within the PON2/CC genotype, but.84 OR  2.9
( ; ) within the PON2/CS95% CI  2.4–3.5 P  .0002
and SS genotypes. A similar gradual increase in the dis-
tribution of the PON2*S allele among the PON1 gen-
otypes was observed in the cases: the frequency of the
PON2*S allele was significantly lower in the PON1/AA
genotype (.51) than in the PON1/AB genotype (.76;
) and the PON1/BB genotype (.84;P  .0003 P 
) (fig. 2). This increase is also seen in the age- and.0001
sex-adjusted ORs for the PON2 dominant model:
( ; ) within theOR  1.1 95% CI  0.1–2.1 P  .87
PON1/AA genotype, but (OR  3.6 95% CI  2.6–
; ) within the PON1/AB and BB genotypes.4.6 P  .011
These, as well as the earlier results regarding the dis-
tribution of PON1 within the PON2 genotypes (table
5), suggest an interaction between these two loci in the
determination of CHD risk. Indeed, if both the PON1
and the PON2 genotypes are included in the model, then
their ORs are 2.4 ( ; ) and95% CI  1.9–2.9 P  .0007
2.1 ( ; ), respectively, both of95% CI  1.4–2.8 P  .040
which are decreased from their univariate values (table
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Table 5
Distribution of PON2 Genotypes, Stratified by Non-PON1*B Carriers and PON1*B Carriers,
and Distribution of PON1 Genotypes, Stratified by Non-PON2*S Carriers and PON2*S
Carriers
NON-PON1*B CARRIERS PON1*B CARRIERS
Controls (n  87) Cases (n  35) Controls (n  93) Cases (n  92)
PON2:
Genotype:
CCa 17 (19.5%) 10 (28.6%) 12 (12.9%) 4 (4.3%)
CS 36 (41.4%) 14 (40.0%) 42 (45.2%) 33 (35.9%)
SSb 34 (39.1%) 11 (31.4%) 39 (41.9%) 55 (59.8%)
Allele:
S (Ser)c .60 .51 .64 .78
C (Cys) .40 .49 .35 .22
NON-PON2*S CARRIERS PON2*S CARRIERS
Controls (n  29) Cases (n  14) Controls (n 151) Cases (n  113)
PON1:
Genotype:
AAd 17 (58.6%) 10 (71.4%) 70 (46.4%) 25 (22.1%)
ABd 9 (31.0%) 3 (21.4%) 61 (40.4%) 70 (62.0%)
BB 3 (10.3%) 1 (7.1%) 20 (13.2%) 18 (15.9%)
Allele
A (Gln)e .74 .82 .67 .53
B (Arg) .26 .18 .33 .47
a Significant difference between cases and controls, among PON1*B carriers: P ! .03.
b Significant difference between cases and controls, among PON1*B carriers: P ! .01.
c Significant difference between cases and controls, among PON1*B carriers: P ! .003.
d Significant difference between cases and controls, among PON2*S carriers: P ! .0001.
e Significant difference between cases and controls, among PON2*S carriers: P ! .001.
4, “PON1 and PON2” model). However, a direct test
of interaction ( )PON1[dominant]# PON2[dominant]
between PON1 and PON2 showed no significant effect
in this sample ( ; ;OR  3.3 95% CI  1.9–4.7 P 
; table 4, “Interaction” model)..090
To further investigate the interaction effects, a risk
variable consisting of the number of high-risk carrier
genotypes that an individual carries (0, 1, or 2, where
0 is [PON1/AA and PON2/CC], 1 is [PON1/AB, BB and
PON2/CC] or [PON1/AA and PON2/CS, SS], and 2 is
[PON1/AB,BB and PON2/CS,SS]) was fitted to the data.
With the 0, or low-risk, carrier genotype as the referent
group, then, for the 1 high-risk genotype the OR was
1.0 ( ) and for the 2 high-risk geno-95% CI  0.1–2.0
type the OR was 3.2 ( ), with overall95% CI  2.3–4.1
. The same result was obtained if this variableP ! .0001
was fitted as a linear effect. However, as for the
interaction effect, the addition of anPON1# PON2
interaction effect (an indicator variable for the presence
of the double-high-risk genotype) did not significantly
improve the fit to the data ( ). Although the in-P  .73
teraction effects were not significant, the OR estimates
(table 4) were suggestive of an interaction between the
PON1 and the PON2 polymorphisms in affecting CHD
risk.
Given that the PON1 and the PON2 genes are linked
on chromosome 7, an interaction effect may be due to
linkage disequilibrium between these two loci. However,
no significant linkage disequilibrium ( ) wasP  .088
seen in controls (tested by omitting the double hetero-
zygotes) (table 6). There was, however, significant link-
age disequilibrium in the cases ( ), which mayP  .0007
be a result of ascertainment with an artificial selection
against the PON1*A-PON2*C low-risk combination.
Linkage disequilibrium was estimated to be D  .023
for controls and for cases (D is estimated asD  .073
described by Hill [1974]).
Relationship between Genotypes and Lipid Variables
Table 7 shows the distribution of valuesmean SE
for age, BMI, and quantitative lipid and apolipoprotein
levels, among different PON2 genotypes, in CHD cases
and in controls. No significant difference was present
among the genotypes, for any of the traits examined.
Discussion
Three independent studies, including one from our
laboratory, have indicated that the PON1 codon 192
polymorphism is a significant risk factor for CHD in
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Table 6
PON1/PON2 Haplotype Frequencies
PON1 PON2
OBSERVED FREQUENCY/EXPECTED
FREQUENCYa
Casesb Controlsc
A C .24/.16 .28/.26
A S .32/.38 .40/.42
B C .05/.14 .10/.12
B S .38/.32 .22/.20
a Observed haplotype frequencies were calculated with the double-
heterozygote individuals (PON1/AB:PON2/CS) omitted; expectedhap-
lotype frequencies were calculated under the assumption of no linkage
disequilibrium.
b D  .073, calculated by use of the iterative method of Hill (1995).
c D  .023, calculated by use of the iterative method of Hill (1995).
Table 7
Age, BMI, and Lipid and Apolipoprotein Concentrations, among PON2 Genotypes in Controls and Cases
CONTROLS CASES
Mean  SE
P
Mean  SE
PCC (n  33) CS (n  80) SS (n  76) CC (n  14) CS (n  42) SS (n  59)
Age (years) 50.6  1.8 48.4  1.2 50.4  1.4 .50 52.3  2.4 57.1  1.4 55.1  1.2 .23
BMI (kg/m2) 24.9  .7 25.1  .4 24.9  .5 .92 25.9  .8 25.0  .5 24.3  .4 .19
HDL choles-
terol (mg/
dl)
44.2  3.1 39.2  1.2 42.1  1.5 .24 28.4  2.3 27.4  1.5 27.2  1.0 .90
LDL choles-
terol (mg/
dl)
166.2  6.2 155.1  4.9 176.6  8.9 .10 166.5  10.8 161.6  5.7 151  5.9 .31
Total choles-
terol (mg/
dl)
242.2  1.0 223.6  1.0 239.9  1.0 .12 219.5  9.0 220.0  5.8 208.8  6.0 .40
Triglycerides
(mg/dl)
154.4  1.1 145.5  1.1 148.4  1.1 .87 126.5  1.1 144.0  1.1 142.6  1.0 .51
Apo A-I (mg/
dl)
149.3  5.4 138.7  2.9 141.1  3.2 .21 89.1  1.2 94.6  1.1 86.5  1.0 .70
Apo B (mg/dl) 145.7  5.2 131.8  3.5 136.3  5.0 .18 108.3  6.3 105.9  4.8 102.3  3.4 .74
populations of Caucasian ancestry (Ruiz et al. 1995;
Serrato and Marian 1995; Sanghera et al. 1997). How-
ever, this association was not confirmed in two Cauca-
sian samples (Antikainen et al. 1996; Herrman et al.
1996) and one Chinese sample (Sanghera et al. 1997).
A possible explanation for this inconsistent association
is that the PON1 codon 192 polymorphism is not di-
rectly related to CHD risk but is in linkage disequilib-
rium with a functional mutation that is directly related
to CHD risk and that is present elsewhere, either in the
PON1 gene or in a nearby gene. Recently, two additional
PON genes, PON2 and PON3, have been described that
are tightly linked with the existing PON1 gene on chro-
mosome 7 (Primo-Parmo et al. 1996a, 1996b). Possibly,
one of these genes harbors a functional mutation, and
the B allele of the PON1 polymorphism merely acts as
a marker for this functional mutation. In their prelim-
inary report, Primo-Parmo et al. (1996b) predicted a
possible polymorphism at codon 311 in the PON2 gene.
In the present investigation, we have confirmed the ex-
istence of a common polymorphism in the PON2 gene
and have investigated its potential involvement in the
susceptibility to CHD in an Asian Indian sample from
Singapore, in which the PON1*B allele was a significant
risk factor for CHD (Sanghera et al. 1997).
Our data indicate that the PON2*S allele is a signif-
icant risk factor for CHD and that its effect is dominant,
with both the PON2/CS and the SS genotypes being
associated with higher risk ( ), compared withOR  2.5
that associated with the CC genotype. However, the
CHD risk associated with the PON2*S allele was con-
fined to individuals who were also carriers of the
PON1*B allele ( in PON1*B carriers vs.OR  3.6
in non-PON1*B carriers), suggesting the pos-OR  1.1
sibility of an interaction between the two polymor-
phisms. The PON1*B allele was not a risk factor among
non-PON2*S carriers ( ), and the same wasOR  0.9
true for the PON2*S allele among non-PON1*B car-
riers ( ). Conversely, among PON1*B carriers,OR  1.1
the PON2*S allele was associated with a significantly
higher risk for development of CHD ( ), and,OR  3.6
among PON2*S carriers, the PON1*B allele was as-
sociated with a significant risk ( ). Further-OR  2.9
more, the parameter estimates for the interaction model
(table 4) and for the high-risk-genotype variable (see the
Results section) suggest that the risk for development of
CHD is present only in those individuals carrying both
high-risk genotypes. However, direct tests for interaction
between these loci show no statistically significant effect,
nor is there any evidence of the significant linkage dis-
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equilibrium between the two loci that is seen in the con-
trols. The acceptance of the “PON1 and PON2” model,
as opposed to either “unigenotype” model—that is
“PON1 Only” and “PON2 Only” (table 4)—indicates
that, in this sample, both the PON1*B allele and the
PON2*S allele contribute to an individual’s suscepti-
bility to CHD. The association of both polymorphisms
with the CHD risk was independent of diabetic status,
because removal of diabetic individuals from the cases
and from the controls did not effect this association.
The physiological mechanism behind these associa-
tions is still not clear. However, our previous (Sanghera
et al. 1997) and current findings on the lack of associ-
ation of the PON1 and PON2 polymorphisms with
plasma lipid and apolipoproteins suggest that CHD risk
is not mediated through the conventional risk factors.
However, in view of the accumulating evidence for PON-
mediated protection of LDL against oxidative modifi-
cations, allelic variations at these loci may be involved
in the determination of an individual’s susceptibility to
LDL oxidation. Possibly, the PON-associated protection
against organophosphate poisoning and oxidative dam-
age is mediated by completely different catalytic centers
(La Du 1996). Unlike PON1, in which none of the three
cysteine residues functions as an active-center cysteine
(Sorenson et al. 1995), PON2 may utilize cysteine for
its catalytic activity, as proposed by Augustinsson
(1968). Therefore, the presence of cysteine at position
311 in the PON2 protein can be hypothesized as a po-
tential activity center for hydrolysis of oxidized lipids,
and its substitution by serine may inhibit its catalytic
activity in the prevention of oxidative damage. Alter-
natively, if cysteine at position 311 is not a key com-
ponent of the activity center for PON2, it may be in-
volved in prevention of stability of the enzyme, by
formation of a disulfide bond that could affect its cat-
alytic efficiency. Additional functional studies are re-
quired in order to determine the role that cysteine at
position 311 has in lipid peroxidation. It is possible that
neither the PON2*S allele nor the PON1*B allele is
functional but that, rather, they are in linkage disequi-
librium with a yet to be determined functional mutation
in the PON gene cluster on chromosome 7. The PON3
gene lies between the other two PON genes, and this
may harbor the functional mutation. A recent report of
a French diabetic sample has indicated that the codon
55 polymorphism in the PON1 gene is an independent
risk factor for CHD and that it can significantly mod-
ulate enzyme concentrations (Blatter Garin et al. 1997).
However, our data indicate that the codon 55 poly-
morphism is not associated with CHD ( D. K. Sanghera,
N. Saha, and M. I. Kamboh, unpublished data). Addi-
tional studies are needed in order to detect new muta-
tions in this gene cluster and to identify the functional
mutation in regard to the risk of CHD.
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